Loading...
XHKG
0867
Market cap2.59bUSD
May 09, Last price  
8.34HKD
1D
-2.23%
1Q
9.88%
Jan 2017
-32.08%
IPO
200.00%
Name

China Medical System Holdings

Chart & Performance

D1W1MN
No data to show
P/E
11.58
P/S
2.51
EPS
0.67
Div Yield, %
3.00%
Shrs. gr., 5y
-0.43%
Rev. gr., 5y
4.22%
Revenues
7.47b
-6.79%
293,521,292378,015,974495,420,948658,586,947876,679,8131,322,320,0051,759,354,0172,201,418,5412,945,131,0003,553,431,0004,900,812,0005,348,838,0005,433,449,0006,073,624,0006,945,964,0008,337,221,0009,150,347,0008,013,285,0007,468,990,000
Net income
1.62b
-32.54%
31,299,16563,444,619101,991,205141,230,145202,871,947391,404,660530,797,280623,144,1781,045,702,000995,935,0001,375,936,0001,674,807,0001,849,883,0001,960,712,0002,530,398,0003,017,402,0003,258,992,0002,400,940,0001,619,788,000
CFO
1.27b
-49.32%
62,309,82248,008,98569,433,996106,168,41674,225,650394,346,040435,615,919327,749,899843,198,000614,552,0001,067,880,0002,071,798,0001,754,565,0002,555,119,0002,692,027,0002,493,852,0003,553,243,0002,502,853,0001,268,547,000
Dividend
Aug 29, 20240.164 HKD/sh
Earnings
Aug 13, 2025

Profile

China Medical System Holdings Limited, an investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People's Republic of China. The company's products include Plendil for the treatment of hypertension and stable angina pectoris; XinHuoSu for the treatment of acute heart failure; Deanxit for the treating mild-to-moderate depression, anxiety, and psychosomatic affections; Ursofalk for the treatment of cholesterol gallstones in the gallbladder, cholestatic liver disease, and biliary reflux gastritis; Salofalk for treating Ulcerative Colitis and Crohn's disease; Bioflor for the treatment of diarrhea; Combizym for dyspepsia; Augentropfen Stulln Mono eye drops to treat senile macula degeneration and asthenopia; and Hirudoid for blunt traumata with or without hematomas and superficial phlebitis insofar. Its products also comprise DanShenTong capsules for treating acne, tonsillitis, otitis externa, boils, carbuncle, traumatic infection, burn infection, mastitis, cellulitis, osteomyelitis, etc.; XiDaKang, a protein hydrolysate oral solution; YiNuoShu for treating respiratory diseases; Ganfule capsules for the treatment of primary cancer of the liver; Imdur for the treatment of coronary heart disease, chronic heart failure, and myocardial infarction, as well as for prevention of vasospasm and mixed angina; and Parlodel tablets for the endocrine and neuro system indications. In addition, the company also offers Elcatonin injection for osteoporosis; YinlianQinggan granules for treating acute hepatitis A and chronic hepatitis B; Lamisil tablets for treating fungal infections on skin and hair; and MOVICOL for treating chronic constipation and faecal impaction. In addition, it is involved in the agriculture and livestock activities. The company was founded in 1995 and is headquartered in North Point, Hong Kong. China Medical System Holdings Limited is a subsidiary of Treasure Sea Limited.
URL
https://web.cms.net.cn/zh/home/
IPO date
Sep 28, 2010
Employees
5,622
Domiciled in
CN
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
7,468,990
-6.79%
8,013,285
-12.43%
9,150,347
9.75%
Cost of revenue
5,818,519
5,267,222
5,597,855
Unusual Expense (Income)
NOPBT
1,650,471
2,746,063
3,552,492
NOPBT Margin
22.10%
34.27%
38.82%
Operating Taxes
397,227
489,341
486,655
Tax Rate
24.07%
17.82%
13.70%
NOPAT
1,253,244
2,256,722
3,065,837
Net income
1,619,788
-32.54%
2,400,940
-26.33%
3,258,992
8.01%
Dividends
(556,162)
(1,360,363)
(1,276,239)
Dividend yield
3.03%
4.01%
4.24%
Proceeds from repurchase of equity
(238,394)
1,272,228
BB yield
1.30%
-4.22%
Debt
Debt current
848,233
1,285,066
1,799,141
Long-term debt
41,953
48,758
42,786
Deferred revenue
Other long-term liabilities
909
Net debt
(6,517,729)
(8,424,368)
(7,807,889)
Cash flow
Cash from operating activities
1,268,547
2,502,853
3,553,243
CAPEX
(32,619)
(27,490)
(524,921)
Cash from investing activities
(615,096)
(442,276)
(1,178,202)
Cash from financing activities
(1,261,046)
(2,125,024)
(1,399,914)
FCF
1,119,027
3,449,074
2,773,614
Balance
Cash
5,866,598
6,143,316
5,867,712
Long term investments
1,541,317
3,614,876
3,782,104
Excess cash
7,034,466
9,357,528
9,192,298
Stockholders' equity
14,134,212
13,258,795
14,392,445
Invested Capital
10,229,386
7,500,616
6,969,183
ROIC
14.14%
31.19%
45.04%
ROCE
9.50%
16.18%
21.81%
EV
Common stock shares outstanding
2,427,382
2,451,989
2,453,940
Price
7.55
-45.45%
13.84
12.70%
12.28
-5.68%
Market cap
18,326,737
-46.00%
33,935,521
12.61%
30,134,386
-6.21%
EV
11,900,647
25,547,352
22,587,217
EBITDA
1,909,709
2,975,628
3,779,718
EV/EBITDA
6.23
8.59
5.98
Interest
38,610
46,251
49,086
Interest/NOPBT
2.34%
1.68%
1.38%